Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Immutep Ltd ( (AU:IMM) ) has provided an update.
Immutep Ltd presented an update at the Jefferies Global Healthcare Conference in June 2025, highlighting its ongoing business activities. The presentation emphasized the company’s commitment to leveraging immune system capabilities to address cancer and autoimmune disorders, which could enhance its market position and influence stakeholders in the biotechnology industry.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on harnessing the power of the immune system to combat cancer and autoimmune diseases. The company operates in the healthcare sector and is listed on both the Australian Securities Exchange (ASX: IMM) and NASDAQ (IMMP).
YTD Price Performance: -21.92%
Average Trading Volume: 4,236,447
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$416.2M
See more data about IMM stock on TipRanks’ Stock Analysis page.